Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-448 dosing regimens in overweight/obese men with hypogonadotropic hypogonadism
2014-002155-25Phase 2Terminated
- Sponsor
- Takeda
- Start
- Aug 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of TAK-448 in hypogonadotropic hypogonadism (HH) (2 arms), sponsored by Takeda. Primary endpoint: Percent change from baseline in AUEC72 of total serum testosterone after 4 weeks. Started Aug 2014; status: terminated.
02
Drugs
TAK-448
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on 2014-002155-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002155-25.